House Medicare Bill Expands Competitive Bidding To DME Infusion Products
This article was originally published in The Gray Sheet
Executive Summary
Device industry concerns that an expanded Medicare competitive bidding program would eventually include new, high-end technologies may be alleviated by language in the "Medicare Prescription Drug & Modernization Act" of 2003, which specifically excludes Class III devices
You may also be interested in...
MedPAC Recommends Methods To Ease Transition To Competitive Bidding
Inclusion of a mandatory trial period in a competitive bidding program that allows Medicare beneficiaries to switch to a non-winning supplier if dissatisfied with the program's quality may be a way to gain beneficiary support for competitive bidding, according to MedPAC's 1June report
MedPAC Recommends Methods To Ease Transition To Competitive Bidding
Inclusion of a mandatory trial period in a competitive bidding program that allows Medicare beneficiaries to switch to a non-winning supplier if dissatisfied with the program's quality may be a way to gain beneficiary support for competitive bidding, according to MedPAC's 1June report
Glucose Monitor Manufacturers Wary As DME Competitive Bidding Looms
Blood glucose monitors and test strips are product areas that may fall under a competitive bidding model in upcoming Medicare reform legislation, according to device stakeholders